CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Rapid HBV DNA decrease is the most important prognostic factor for first line treatment with Adefovir dipivoxil in HBeAg positive and negative patients with chronic hepatitis B
DOI 10.1055/s-0028-1089431
Bibliografische Angaben
Nachweis in CareLit
Autor:innenHG Hass, T Bock, O Nehls, S Kaiser
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: In the present study the nucleoside analogue adefovir dipivoxil (ADV) was used as first-line monotherapy for treatment of CHB in treatment-naive patients. The aim was to estimate the effect of viral factors such as HBV genotype, viral load and viral kinetics on treatment response after 48 and 96 weeks. Methods: Data of sixty-six patients (60% males, 65% HBeAg negative) were analyzed. All patients received 10mg…
Zitieren
Zitierempfehlung
HG Hass, T Bock, O Nehls, S Kaiser (2008) Rapid HBV DNA decrease is the most important prognostic factor for first line treatment with Adefovir dipivoxil in HBeAg positive and negative patients with chronic hepatitis B. Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0028-1089431
Mit CareLit weiterarbeiten